115 related articles for article (PubMed ID: 35720961)
21. Adverse events following immunization of ChAdOx1 nCoV-19 vaccine among healthcare workers of a medicine-teaching institution of North India.
Jha A; Kumar P; Goel SK; Bharatwal AA; Dhamnetiya D; Singh S; Jha RP
J Family Med Prim Care; 2024 Jan; 13(1):298-310. PubMed ID: 38482279
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Adverse Events Following COVID-19 Vaccination: A Cross-sectional Study in Ibadan, Nigeria.
Alao MA; Ogunbosi BO; Ibrahim OR; Oladokun RE; Lagunju IA
Niger Med J; 2022; 63(3):248-258. PubMed ID: 38835530
[TBL] [Abstract][Full Text] [Related]
23. A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India.
Kaur U; Ojha B; Pathak BK; Singh A; Giri KR; Singh A; Das A; Misra A; Yadav AK; Kansal S; Chakrabarti SS
EClinicalMedicine; 2021 Aug; 38():101038. PubMed ID: 34505032
[TBL] [Abstract][Full Text] [Related]
24. Adverse Events Following the First Dose of Immunization of COVID-19 Vaccine.
Bhandari B; Jha N; Khan IH; Rayamajhi G; Thapa L; Bista B
J Nepal Health Res Counc; 2022 Jun; 20(1):59-64. PubMed ID: 35945854
[TBL] [Abstract][Full Text] [Related]
25. Rates, types, and associated factors of acute adverse effects after the first dose of ChAdOx1 nCoV-19 vaccine administration in Thailand.
Watcharananan SA; Nadee C; Kongsuwattanaleart P; Sangthong N; Ngorsakun P; Vimonvattaravetee P; Phuphuakrat A; Udomsubpayakul U
IJID Reg; 2022 Mar; 2():35-39. PubMed ID: 35721432
[TBL] [Abstract][Full Text] [Related]
26. Incidence and clinical characteristics of adverse neurological events and stroke-like syndrome associated with immune stress-related response after COVID-19 vaccination in 2021 from Thailand.
Sirisuk W; Limvorapitak W; Lolekha P; Methaset K; Kulkantrakorn K
Clin Neurol Neurosurg; 2023 Aug; 231():107804. PubMed ID: 37295197
[TBL] [Abstract][Full Text] [Related]
27. More Than Three-Fourths of AstraZeneca (ChAdox1 COV-19) COVID-19 Vaccinated Individuals Develop Post Immunization Adverse Event in Northwest Ethiopia.
Muluneh AG; Merid MW; Gelaye KA; Tilahun SY; Teshager NW; Abereha AY; Sugamo KS; Yimer MA; Kassa GM
Infect Drug Resist; 2022; 15():2409-2416. PubMed ID: 35535029
[TBL] [Abstract][Full Text] [Related]
28. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: An analysis of nationwide causality assessment from India.
Gandhi AP; Venkatesh U; Murali N
Indian Heart J; 2023; 75(2):139-144. PubMed ID: 36863611
[TBL] [Abstract][Full Text] [Related]
29. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
[TBL] [Abstract][Full Text] [Related]
30. A Retrospective Cross-Sectional Study Assessing Self-Reported Adverse Events following Immunization (AEFI) of the COVID-19 Vaccine in Bangladesh.
Sultana A; Shahriar S; Tahsin MR; Mim SR; Fatema KR; Saha A; Yesmin F; Bahar NB; Samodder M; Mamun MAH; Aknur Rahman M; Ferdousy S; Akter T; Aktar F; Kuddus MR; Rahman MM; Sarker MMR; Büyüker SM; Chowdhury JA; Chowdhury AA; Kabir S; Hossain MA; Amran MS
Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696198
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review.
Mahroum N; Lavine N; Ohayon A; Seida R; Alwani A; Alrais M; Zoubi M; Bragazzi NL
Front Immunol; 2022; 13():872683. PubMed ID: 35865539
[TBL] [Abstract][Full Text] [Related]
32. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
33. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Covishield
Murali S; Sakthivel M; Pattabi K; Venkatasamy V; Thangaraj JWV; Shete A; Varghese AJ; Arjun J; Kumar CPG; Yadav PD; Sahay R; Majumdar T; Dudhmal M; Sivalingam A; Dhanapal SR; Durai Samy A; Radhakrishnan V; Muni Krishnaiah MM; Arunachalam S; Gandhi PMK; Govindasamy E; Chinnappan P; Sekar DPV; Marappan P; Pounraj E; Ganeshkumar P; Jagadeesan M; Narnaware M; Bedi GS; Kaur P; Murhekar M
Vaccines (Basel); 2022 Jun; 10(6):. PubMed ID: 35746578
[TBL] [Abstract][Full Text] [Related]
35. Adverse events and breakthrough infections associated with COVID-19 vaccination in the Indian population.
Arora G; Taneja J; Bhardwaj P; Goyal S; Naidu K; Yadav SK; Saluja D; Jetly S
J Med Virol; 2022 Jul; 94(7):3147-3154. PubMed ID: 35261064
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 vaccination: Is it a matter of concern?
Kushwaha P; Pundhir A; Gahlot A
J Family Med Prim Care; 2022 Jun; 11(6):2431-2436. PubMed ID: 36119229
[TBL] [Abstract][Full Text] [Related]
37. Psychological and Psychiatric Events Following Immunization with Five Different Vaccines against SARS-CoV-2.
García-Alanis M; Morales-Cárdenas M; Toapanta-Yanchapaxi LN; Chiquete E; Núñez I; Ceballos-Liceaga SE; Carbajal-Sandoval G; Toledo-Salinas C; Mendoza-Hernández DA; Scheffler-Mendoza SC; Ortega-Martell JA; Carrillo-García DA; Hernández-Valdivia N; Gutiérrez-Romero A; Galnares-Olalde JA; Flores-Silva FD; Díaz-Ortega JL; Reyes-Terán G; López-Gatell H; Cortes-Alcalá R; Pérez-Padilla JR; Arauz A; García-Grimshaw M; Valdés-Ferrer SI
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016185
[TBL] [Abstract][Full Text] [Related]
38. Vaccine effectiveness to protect against moderate or severe disease in COVID cases: A prospective cohort study.
Joshi RK; Muralidharan CG; Ahuja A; Mukherjee R; Chaurasia S; Manjaly L; Divyanshi ; Sahoo AK; Gosavi J; Thomas A
Med J Armed Forces India; 2022 Apr; 79(Suppl 1):S102-11. PubMed ID: 35400799
[TBL] [Abstract][Full Text] [Related]
39. Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India.
Basavaraja CK; Sebastian J; Ravi MD; John SB
Ther Adv Vaccines Immunother; 2021; 9():25151355211055833. PubMed ID: 34841193
[TBL] [Abstract][Full Text] [Related]
40. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
